Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Arlene B Chapman¹, Olivier Devuyst², Kai-Uwe Eckardt³, Ron T Gansevoort⁴, Tess Harris⁵, Shigeo Horie⁶, Bertram L Kasiske⁷, Dwight Odland⁸, York Pei⁹, Ronald D Perrone¹⁰, Yves Pirson¹¹, Robert W Schrier¹², Roser Torra¹³, Vicente E Torres¹⁴, Terry Watnick¹⁵, David C Wheeler¹⁶; Conference Participants

Collaborators, Affiliations

Collaborators

Conference Participants:
Curie Ahn, Ahsan Alam, Béatrice Aussilhou, Kyongtae T Bae, William M Bennett, Carsten Bergmann, Daniel G Bichet, Klemens Budde, Dominique Chauveau, Benjamin Cowley, Brenda de Coninck, Katherine M Dell, Joost P H Drenth, Tevfik Ecder, Francesco Emma, Claude Férec, Bruno Flamion, Flavia Galletti, Bernice Gitomer, Jared J Grantham, Nicole Harr, Peter C Harris, Eiji Higashihara, Eiko Hodouchi, Marie C Hogan, Vivek Jha, Uwe Korst, Corinne Lagrafeuil, Rodolfo S Martin, Michal Mrug, Gregorio T Obrador, Albert C M Ong, Luiz F Onuchic, Luisa Sternfeld, Gopala K Rangan, Richard Sandford, Andreas L Serra, Theodore I Steinman, Svend Strandgaard, Gerd Walz, Christopher G Winearls, Kaori Yamane Winston

Affiliations

¹ Emory University School of Medicine, Atlanta, Georgia, USA.
² Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
³ University of Erlangen-Nürnberg, Erlangen, Germany.
⁴ University Medical Center Groningen, Groningen, The Netherlands.
⁵ PKD International, Geneva, Switzerland.
⁶ Juntendo University Graduate School of Medicine, Bunkyou, Tokyo, Japan.
⁷ Hennepin County Medical Center, Minneapolis, Minnesota, USA.
⁸ PKD Foundation, Kansas City, Missouri, USA.
⁹ University Health Network, University of Toronto, Toronto, Ontario, Canada.
¹⁰ Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.
¹¹ Université Catholique de Louvain, Brussels, Belgium.
¹² University of Colorado, Denver, Colorado, USA.
¹³ Fundació Puigvert, REDinREN, Universitat Autónoma de Barcelona, Barcelona, Spain.
¹⁴ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹⁶ University College London, London, UK.

PMID: 25786098
PMCID: PMC4913350
DOI: 10.1038/ki.2015.59

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Arlene B Chapman et al. Kidney Int. 2015 Jul.

. 2015 Jul;88(1):17-27.

doi: 10.1038/ki.2015.59. Epub 2015 Mar 18.

Authors

Collaborators

Conference Participants:
Curie Ahn, Ahsan Alam, Béatrice Aussilhou, Kyongtae T Bae, William M Bennett, Carsten Bergmann, Daniel G Bichet, Klemens Budde, Dominique Chauveau, Benjamin Cowley, Brenda de Coninck, Katherine M Dell, Joost P H Drenth, Tevfik Ecder, Francesco Emma, Claude Férec, Bruno Flamion, Flavia Galletti, Bernice Gitomer, Jared J Grantham, Nicole Harr, Peter C Harris, Eiji Higashihara, Eiko Hodouchi, Marie C Hogan, Vivek Jha, Uwe Korst, Corinne Lagrafeuil, Rodolfo S Martin, Michal Mrug, Gregorio T Obrador, Albert C M Ong, Luiz F Onuchic, Luisa Sternfeld, Gopala K Rangan, Richard Sandford, Andreas L Serra, Theodore I Steinman, Svend Strandgaard, Gerd Walz, Christopher G Winearls, Kaori Yamane Winston

Affiliations

¹ Emory University School of Medicine, Atlanta, Georgia, USA.
² Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
³ University of Erlangen-Nürnberg, Erlangen, Germany.
⁴ University Medical Center Groningen, Groningen, The Netherlands.
⁵ PKD International, Geneva, Switzerland.
⁶ Juntendo University Graduate School of Medicine, Bunkyou, Tokyo, Japan.
⁷ Hennepin County Medical Center, Minneapolis, Minnesota, USA.
⁸ PKD Foundation, Kansas City, Missouri, USA.
⁹ University Health Network, University of Toronto, Toronto, Ontario, Canada.
¹⁰ Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.
¹¹ Université Catholique de Louvain, Brussels, Belgium.
¹² University of Colorado, Denver, Colorado, USA.
¹³ Fundació Puigvert, REDinREN, Universitat Autónoma de Barcelona, Barcelona, Spain.
¹⁴ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹⁶ University College London, London, UK.

PMID: 25786098
PMCID: PMC4913350
DOI: 10.1038/ki.2015.59

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries. The Kidney Disease: Improving Global Outcomes Controversies Conference on ADPKD brought together a panel of multidisciplinary clinical expertise and engaged patients to identify areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support. These are summarized in this review.

PubMed Disclaimer

References

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–1301. - PubMed
1. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122–2130. - PubMed
1. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479–486. - PMC - PubMed
1. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1:148–157. - PubMed
1. Paul BM, Consugar MB, Ryan Lee M, et al. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int. 2014;85:383–392. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Collaborators

Affiliations

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Authors

Collaborators

Affiliations

Abstract

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical